首页 | 官方网站   微博 | 高级检索  
     

人生长激素治疗垂体性侏儒症的效力及安全性评价
引用本文:林丽香,陈萱林,杨周榕.人生长激素治疗垂体性侏儒症的效力及安全性评价[J].中国新药与临床杂志,1997(2).
作者姓名:林丽香  陈萱林  杨周榕
作者单位:福建省立医院内分泌科
摘    要:目的:对生物合成人生长激素(hGH)治疗垂体性侏儒症的效力及安全性进行评价。方法:垂体性侏儒症16例,男性,其中12例年龄11±s3a(7~15a),骨龄5±3a(2~10a),4例年龄18.0±1.4a(16~19a),骨龄12.7±1.2a(11~14a)。给予hGH,每日剂量0.1IU/(kg·d),sc,6~12mo。结果:骨龄≤11a的年身高增长速率11.0±1.2cm(P<0.05),骨龄>11a的年身高增长速率10.0±1.0cm(P<0.05),副作用少,治疗期对血液生化无不良影响。结论:hGH对垂体性侏儒症的治疗效果满意,安全性好。

关 键 词:生长激素  垂体性侏儒症  安全  骨胳测定年龄

New Drugs and Clinical Remedies 1997 Mar; 16(2):81-82 Evaluation of efficacy and safety of human growth-hormone in treating pituitary dwarfism
LIN Li-Xiang,CHEN Xuan-Lin,YANG Zhou-Rong.New Drugs and Clinical Remedies 1997 Mar; 16(2):81-82 Evaluation of efficacy and safety of human growth-hormone in treating pituitary dwarfism[J].Chinese Journal of New Drugs and Clinical Remedies,1997(2).
Authors:LIN Li-Xiang  CHEN Xuan-Lin  YANG Zhou-Rong
Abstract:AIM: To evaluate the efficacy and safety of human growth-hormone (hGH) in treating pituitary dwarfism. METHODS: Sixteen patients with pituritary dwarfs(M 12, age 11±s 3 a, bone age 5±3 a; M4, age 18.0±1.4 a, bone age 12.7±1.2 a) received hGH 0.1 IU/(kg·d), sc, dialy ×6-12 mo. RESULTS: Twelve patients with bone age <11 a had a height increase of 11.0±1.2 cm/a, while the other 4 patients with bone age >11 a had a height increase of 10.0±1.0 cm/a (P<0.05). No adverse reaction and harmful effects on blood biochemical change were found. CONCLUSION: hGH is effective and safe in treating pituitary dwarfism.
Keywords:somatotropin  pituitary dwarfism  safety  age determination by skeleton  
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号